AAVogen, Inc. With a mission to make you stronger, AAVogen is at the forefront of muscle gene therapy. Led by renowned founder and CEO, Dr.

Buel Dan Rodgers, the team boasts an impressive 27 years of research experience in skeletal and cardiac muscle development. Their expertise extends to various fields, including business/product development, regulatory affairs, CMC, preclinical development, and more. Additionally, AAVogen benefits from a distinguished Science Advisory Board, comprised of esteemed experts in gene therapy, muscle disease, and molecular biology.

Together, they form a muscle gene therapy dream team. AAVogen's innovative pipeline focuses on addressing important disease indications such as muscular dystrophies, cancer cachexia, and inclusion body myositis. The company is committed to developing viral gene delivery systems and AAV-based gene therapeutics to revolutionize the treatment of these conditions.

As AAVogen seeks financing and establishes a Board of Directors, they welcome collaboration, licensing, and investment opportunities. Join them on their mission to transform lives through cutting-edge muscle gene therapy